MedPath

International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study

Not Applicable
Conditions
Breast Cancer
Registration Number
JPRN-UMIN000029029
Lead Sponsor
AstraZeneca K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
45
Inclusion Criteria

Not provided

Exclusion Criteria

1. Previous enrolment in this study. 2. Involvement in the planning and/or conduct of this study (applies to both AstraZeneca staff and/or staff at the study site). 3. Current participation in a clinical study with an investigational oncology product. 4. Previous PARPi therapy, including, but not limited to, participation in a previous clinical study that included PARPi therapy. 5. Current commencement of PARPi treatment.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the prevalence of gBRCA gene mutations
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath